WO2000026224A3 - Novel macrolide antibiotics - Google Patents

Novel macrolide antibiotics Download PDF

Info

Publication number
WO2000026224A3
WO2000026224A3 PCT/IB1999/001701 IB9901701W WO0026224A3 WO 2000026224 A3 WO2000026224 A3 WO 2000026224A3 IB 9901701 W IB9901701 W IB 9901701W WO 0026224 A3 WO0026224 A3 WO 0026224A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
formula
macrolide antibiotics
novel macrolide
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1999/001701
Other languages
French (fr)
Other versions
WO2000026224A2 (en
Inventor
Takushi Kaneko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EEP200100245A priority Critical patent/EE200100245A/en
Priority to PL99348114A priority patent/PL348114A1/en
Priority to HR20010306A priority patent/HRP20010306A2/en
Priority to KR1020017005535A priority patent/KR20010083944A/en
Priority to IL14262899A priority patent/IL142628A0/en
Priority to TR2002/00435T priority patent/TR200200435T2/en
Priority to JP2000579612A priority patent/JP4043191B2/en
Priority to BR9914998-2A priority patent/BR9914998A/en
Priority to CA002349338A priority patent/CA2349338C/en
Priority to AU59952/99A priority patent/AU5995299A/en
Priority to APAP/P/2001/002131A priority patent/AP2001002131A0/en
Priority to EP99971424A priority patent/EP1124837A2/en
Priority to SK581-2001A priority patent/SK5812001A3/en
Priority to HK03101144.0A priority patent/HK1049010A1/en
Priority to HU0104192A priority patent/HUP0104192A3/en
Priority to EA200100396A priority patent/EA200100396A1/en
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2000026224A2 publication Critical patent/WO2000026224A2/en
Publication of WO2000026224A3 publication Critical patent/WO2000026224A3/en
Priority to IS5919A priority patent/IS5919A/en
Priority to NO20012155A priority patent/NO20012155L/en
Anticipated expiration legal-status Critical
Priority to BG105543A priority patent/BG105543A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

This invention relates to compounds of formula (I) wherein a, R?1, R2, R3, R4, R5, R6¿ and X are each as defined above, and to pharmaceutically acceptable salts thereof, useful as potent antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula (I) and to methods of treating bacterial and protozoal infections by administering the compounds of formula (I).
PCT/IB1999/001701 1998-11-03 1999-10-18 Novel macrolide antibiotics Ceased WO2000026224A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
APAP/P/2001/002131A AP2001002131A0 (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics.
HR20010306A HRP20010306A2 (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics
KR1020017005535A KR20010083944A (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics
IL14262899A IL142628A0 (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics
TR2002/00435T TR200200435T2 (en) 1998-11-03 1999-10-18 New macrolide antibiotics.
PL99348114A PL348114A1 (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics
BR9914998-2A BR9914998A (en) 1998-11-03 1999-10-18 Macrolid antibiotics
CA002349338A CA2349338C (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics
AU59952/99A AU5995299A (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics
EP99971424A EP1124837A2 (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics
JP2000579612A JP4043191B2 (en) 1998-11-03 1999-10-18 New macrolide antibiotics
EEP200100245A EE200100245A (en) 1998-11-03 1999-10-18 New macrolide antibiotics
HK03101144.0A HK1049010A1 (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics
HU0104192A HUP0104192A3 (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics
EA200100396A EA200100396A1 (en) 1998-11-03 1999-10-18 NEW MACROLIDE ANTIBIOTICS
SK581-2001A SK5812001A3 (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics
IS5919A IS5919A (en) 1998-11-03 2001-04-17 New macrolide antibiotics
NO20012155A NO20012155L (en) 1998-11-03 2001-05-02 New macrolide antibiotics
BG105543A BG105543A (en) 1998-11-03 2001-05-29 Novel macrolide antibiotics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10683698P 1998-11-03 1998-11-03
US60/106,836 1998-11-03

Publications (2)

Publication Number Publication Date
WO2000026224A2 WO2000026224A2 (en) 2000-05-11
WO2000026224A3 true WO2000026224A3 (en) 2000-11-16

Family

ID=22313524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001701 Ceased WO2000026224A2 (en) 1998-11-03 1999-10-18 Novel macrolide antibiotics

Country Status (34)

Country Link
US (3) US20020040007A1 (en)
EP (1) EP1124837A2 (en)
JP (1) JP4043191B2 (en)
KR (1) KR20010083944A (en)
CN (1) CN1376160A (en)
AP (1) AP2001002131A0 (en)
AU (1) AU5995299A (en)
BG (1) BG105543A (en)
BR (1) BR9914998A (en)
CA (1) CA2349338C (en)
CO (1) CO5140110A1 (en)
CZ (1) CZ20011512A3 (en)
EA (1) EA200100396A1 (en)
EE (1) EE200100245A (en)
GT (1) GT199900192A (en)
HK (1) HK1049010A1 (en)
HR (1) HRP20010306A2 (en)
HU (1) HUP0104192A3 (en)
ID (1) ID28286A (en)
IL (1) IL142628A0 (en)
IS (1) IS5919A (en)
MA (1) MA26703A1 (en)
NO (1) NO20012155L (en)
OA (1) OA11670A (en)
PA (1) PA8485101A1 (en)
PE (1) PE20001289A1 (en)
PL (1) PL348114A1 (en)
SK (1) SK5812001A3 (en)
SV (1) SV1999000188A (en)
TN (1) TNSN99205A1 (en)
TR (4) TR200101241T2 (en)
UY (1) UY25780A1 (en)
WO (1) WO2000026224A2 (en)
ZA (1) ZA200103289B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP9801420A0 (en) * 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
KR20010083944A (en) 1998-11-03 2001-09-03 실버스타인 아써 에이. Novel macrolide antibiotics
CA2359708C (en) 1999-01-27 2005-10-25 Pfizer Products Inc. Ketolide antibiotics
ID30547A (en) 1999-04-16 2001-12-20 Kosan Biosciences Inc ANTI-INFECTION OF MACROLIDES
US6590083B1 (en) 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
IL145976A0 (en) 1999-04-16 2002-07-25 Ortho Mcneil Pharm Inc Ketolide antibacterials
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
US6514944B2 (en) 1999-04-16 2003-02-04 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6451768B1 (en) 1999-04-16 2002-09-17 Kosan Biosciences, Inc. Macrolide antiinfective agents
EA200100983A1 (en) 1999-05-24 2002-10-31 Пфайзер Продактс Инк. DERIVATIVES 13-METHYLERITROMYCIN
EP1114826A3 (en) * 1999-12-29 2001-10-31 Pfizer Products Inc. Novel antibacterial and prokinetic macrolides
EP1146051A3 (en) * 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A derivatives
DE60104240T2 (en) * 2000-06-30 2005-08-04 Pfizer Products Inc., Groton Macrolide antibiotics
JP2008508322A (en) * 2004-07-28 2008-03-21 ランバクシー ラボラトリーズ リミテッド Ketolide derivatives as antibacterial agents
EP1807439A2 (en) * 2004-10-25 2007-07-18 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
UA85937C2 (en) 2004-12-21 2009-03-10 Пфайзер Продактс Інк. Macrolide compounds
EP1960413A2 (en) * 2005-11-23 2008-08-27 Ranbaxy Laboratories Limited Macrolides derivatives as antibacterial agents
WO2007060518A2 (en) * 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
US7801502B2 (en) * 2006-12-18 2010-09-21 Aai Corporation Method for implementing continuous radio frequency (RF) alignment in advanced electronic warfare (EW) signal stimulation systems
US8409628B2 (en) 2010-02-04 2013-04-02 Penguin IP Holdings, Inc. Methods and compositions for oxygenation of skin to treat skin disorders
US8900601B2 (en) 2010-03-31 2014-12-02 Jennifer Bartels Permeable mixtures, methods and compositions for the skin
AU2014262127B2 (en) * 2013-05-01 2019-05-02 Neoculi Pty Ltd Methods for treating bacterial infections
RU2537143C1 (en) * 2013-11-08 2014-12-27 Государственное научное учреждение Ставропольский научно-исследовательский институт животноводства и кормопроизводства РАСХН Preparation for treatment and prevention of mastitis in cows
WO2018080072A2 (en) * 2016-10-27 2018-05-03 한국생명공학연구원 Novel macrolide-based compound, method for producing same, and pharmaceutical composition for preventing or treating malaria and containing same as active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439889A (en) * 1993-03-09 1995-08-08 Roussel Uclaf Erythromycin derivatives
US5444051A (en) * 1990-11-21 1995-08-22 Roussel Uclaf Erythromycin compounds
WO1998009978A1 (en) * 1996-09-04 1998-03-12 Abbott Laboratories 6-o-substituted ketolides having antibacterial activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (en) 1992-11-05 1994-12-23 Roussel Uclaf New erythromycin derivatives, their preparation process and their use as drugs.
US5332807A (en) 1993-04-14 1994-07-26 Merck & Co., Inc. Process of producing 8A- and 9A-azalide antibiotics
HRP931480B1 (en) 1993-12-08 1997-08-31 Sour Pliva 9a-N-(N'-CARBAMONYL) and 9a-N-(N'-THIOCARBAMONYL) DERIVATES OF 9-DEOXO-9a-HOMOERYTHROMYCIN A
HRP950145A2 (en) * 1995-03-27 1997-08-31 Sour Pliva New compounds of the secomacrolide and secoazalide class and a process for the preparation thereof
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
CA2253338C (en) 1996-05-07 2007-05-08 Abbott Laboratories 6-o-substituted erythromycins and method for making them
AP1029A (en) 1996-07-05 2001-12-11 Biotica Tech Limited Erythromycins and process for their preparation.
UA51730C2 (en) 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-0-substituted ketolides having antibacterial activity
HRP960497B1 (en) * 1996-10-28 2003-08-31 Pliva Pharm & Chem Works 9-n-ethenyl derivatives of 9(s)-erythromycylamine
HN1998000074A (en) 1997-06-11 1999-01-08 Pfizer Prod Inc DERIVATIVES FROM MACROLIDES C-4 SUBSTITUTED
US6407074B1 (en) * 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
EP0895999A1 (en) * 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
US6339063B1 (en) 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
SI1036083T1 (en) * 1997-10-16 2004-10-31 Pliva-Istra�iva�ki institut d.o.o. Novel 9a-azalides
PT941998E (en) * 1998-03-03 2004-12-31 Pfizer Prod Inc MACROLIDAN ANTIBIOTICS OF TYPE 3,6-CETAL
KR20010083944A (en) 1998-11-03 2001-09-03 실버스타인 아써 에이. Novel macrolide antibiotics
EA200100983A1 (en) 1999-05-24 2002-10-31 Пфайзер Продактс Инк. DERIVATIVES 13-METHYLERITROMYCIN
EP1114826A3 (en) 1999-12-29 2001-10-31 Pfizer Products Inc. Novel antibacterial and prokinetic macrolides
EP1122261A3 (en) 2000-01-31 2001-09-26 Pfizer Products Inc. 13 and 14-membered antibacterial macrolides
DE60104240T2 (en) 2000-06-30 2005-08-04 Pfizer Products Inc., Groton Macrolide antibiotics
WO2003004509A2 (en) 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444051A (en) * 1990-11-21 1995-08-22 Roussel Uclaf Erythromycin compounds
US5439889A (en) * 1993-03-09 1995-08-08 Roussel Uclaf Erythromycin derivatives
WO1998009978A1 (en) * 1996-09-04 1998-03-12 Abbott Laboratories 6-o-substituted ketolides having antibacterial activity

Also Published As

Publication number Publication date
CO5140110A1 (en) 2002-03-22
PE20001289A1 (en) 2000-11-22
HRP20010306A2 (en) 2002-06-30
BG105543A (en) 2001-12-29
US6835716B2 (en) 2004-12-28
PL348114A1 (en) 2002-05-06
US7071170B2 (en) 2006-07-04
IL142628A0 (en) 2002-03-10
MA26703A1 (en) 2004-12-20
TR200200436T2 (en) 2002-06-21
BR9914998A (en) 2001-07-10
TNSN99205A1 (en) 2005-11-10
HUP0104192A3 (en) 2003-12-29
AU5995299A (en) 2000-05-22
NO20012155D0 (en) 2001-05-02
TR200200435T2 (en) 2002-07-22
TR200200434T2 (en) 2002-09-23
US20030013665A1 (en) 2003-01-16
NO20012155L (en) 2001-07-02
EP1124837A2 (en) 2001-08-22
WO2000026224A2 (en) 2000-05-11
SK5812001A3 (en) 2001-12-03
IS5919A (en) 2001-04-17
CA2349338A1 (en) 2000-05-11
CN1376160A (en) 2002-10-23
EE200100245A (en) 2002-10-15
HK1049010A1 (en) 2003-04-25
ZA200103289B (en) 2002-08-28
AP2001002131A0 (en) 2001-06-30
JP2002528553A (en) 2002-09-03
ID28286A (en) 2001-05-10
TR200101241T2 (en) 2001-09-21
SV1999000188A (en) 2000-10-16
HUP0104192A2 (en) 2002-02-28
US20020040007A1 (en) 2002-04-04
EA200100396A1 (en) 2001-10-22
KR20010083944A (en) 2001-09-03
JP4043191B2 (en) 2008-02-06
CZ20011512A3 (en) 2001-09-12
CA2349338C (en) 2005-12-06
OA11670A (en) 2005-01-12
UY25780A1 (en) 2001-08-27
PA8485101A1 (en) 2002-08-26
US20050004047A1 (en) 2005-01-06
GT199900192A (en) 2001-04-26

Similar Documents

Publication Publication Date Title
WO2000026224A3 (en) Novel macrolide antibiotics
WO2000044761A3 (en) Ketolide antibiotics
CA2292359A1 (en) Novel azalides and methods of making same
AU6484199A (en) Carbamate and carbazate ketolide antibiotics
MY122353A (en) 13-membered azalides and their use as antibiotic agents
DK1132392T3 (en) Ketolide antibiotics
CA2280328A1 (en) C11 carbamates of macrolide antibacterials
WO1999057125A3 (en) Hygromycin a derivatives
EP1114826A3 (en) Novel antibacterial and prokinetic macrolides
IL126625A0 (en) 6-o-substituted erythromycin compounds and method for making same
CA2351829A1 (en) Macrolide antibiotics
WO2002018353A3 (en) Oxazolidinone chemotherapeutic agents
CA2331261A1 (en) 2"-deoxy hygromycin derivatives
CA2352332A1 (en) Hygromycin a derivatives
BG106635A (en) Hygromycin a prodrugs
CA2563965A1 (en) 6-0-substituted ketolides having antibacterial activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99812941.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 142628

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 511198

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 59952/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200100381

Country of ref document: VN

Ref document number: P-310/01

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: PV2001-1512

Country of ref document: CZ

Ref document number: 5812001

Country of ref document: SK

Ref document number: 200100396

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P20010306A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2349338

Country of ref document: CA

Ref document number: 2349338

Country of ref document: CA

Kind code of ref document: A

Ref document number: 20010351

Country of ref document: UZ

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 579612

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999971424

Country of ref document: EP

Ref document number: PA/a/2001/004418

Country of ref document: MX

Ref document number: 1020017005535

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001/01241

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 1999 105543

Country of ref document: BG

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1999971424

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017005535

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-1512

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002/00435

Country of ref document: TR

Ref document number: 2002/00436

Country of ref document: TR

Ref document number: 2002/00434

Country of ref document: TR

WWR Wipo information: refused in national office

Ref document number: 1020017005535

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999971424

Country of ref document: EP